SymBio Pharmaceuticals Limited - Product Pipeline Review - Q1 2011

Global Markets Direct, May 2011, Pages: 45

SymBio Pharmaceuticals Limited – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “SymBio Pharmaceuticals Limited - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- SymBio Pharmaceuticals Limited - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of SymBio Pharmaceuticals Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of SymBio Pharmaceuticals Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the SymBio Pharmaceuticals Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate SymBio Pharmaceuticals Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of SymBio Pharmaceuticals Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the SymBio Pharmaceuticals Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with SymBio Pharmaceuticals Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of SymBio Pharmaceuticals Limited and identify potential opportunities in those areas.

List of Tables
List of Figures
SymBio Pharmaceuticals Limited Snapshot
SymBio Pharmaceuticals Limited Overview
Key Information
Key Facts
SymBio Pharmaceuticals Limited – Research and Development Overview
Key Therapeutic Areas
SymBio Pharmaceuticals Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
SymBio Pharmaceuticals Limited – Pipeline Products Glance
SymBio Pharmaceuticals Limited – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
SymBio Pharmaceuticals Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
SymBio Pharmaceuticals Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
SymBio Pharmaceuticals Limited – Drug Profiles
SyB L-0501
Product Description
Mechanism of Action
R&D Progress
SyB L-0501 + Rituxan
Product Description
Mechanism of Action
R&D Progress
SyB D-0701
Product Description
Mechanism of Action
R&D Progress
SyB-0702
Product Description
Mechanism of Action
R&D Progress
SymBio Pharmaceuticals Limited – Pipeline Analysis
SymBio Pharmaceuticals Limited – Pipeline Products by Therapeutic Class
SymBio Pharmaceuticals Limited - Pipeline Products By Target
SymBio Pharmaceuticals Limited – Pipeline Products by Route of Administration
SymBio Pharmaceuticals Limited – Pipeline Products by Molecule Type
SymBio Pharmaceuticals Limited – Recent Pipeline Updates
SymBio Pharmaceuticals Limited – Locations And Subsidiaries
Head Office
Financial Deals Landscape
SymBio Pharmaceuticals Limited, Deals Volume Summary, 2004 to YTD 2011
SymBio Pharmaceuticals Limited, Deals Summary By Region, 2004 to YTD 2011
SymBio Pharmaceuticals Limited, Deals Summary, 2004 to YTD 2011
SymBio Pharmaceuticals Limited Detailed Deal Summary
Venture Financing
SymBio Pharmaceuticals Secures $8 Million In Second Tranche Of Series D Financing
SymBio Pharmaceuticals Raises $14.5 Million In Series B Financing
SymBio Pharmaceuticals Raises $9 Million In Series A Financing
Licensing Agreements
SymBio Pharmaceuticals Enters Into License Agreement With Eisai For SyB L-0501
Cephalon Enters Into Licensing Agreement With SymBio Pharmaceuticals
SymBio Pharmaceuticals Signs An Agreement With Eisai
SymBio Pharmaceuticals Enters Into Licensing Agreement With Yuhan Yang Haeng
SymBio Pharmaceuticals Enters Into Licensing Agreement With INNOPHARMAX
SymBio Pharmaceuticals Enters Into Licensing Agreement With Professor Hiroshi Maeda
SymBio Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Abeille Pharmaceuticals Enters Into Licensing Agreement With SymBio Pharmaceuticals
SymBio Pharmaceuticals Enters Into Licensing Agreement With Astellas Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
SymBio Pharmaceuticals Limited – Pipeline by Therapy Area and Indication, 2011
SymBio Pharmaceuticals Limited – Pipeline by Stage of Development, 2011
SymBio Pharmaceuticals Limited – Monotherapy Products in Pipeline, 2011
SymBio Pharmaceuticals Limited – Combination Treatment Modalities in Pipeline, 2011
SymBio Pharmaceuticals Limited – Filed, 2011
SymBio Pharmaceuticals Limited - Phase II, 2011
SymBio Pharmaceuticals Limited - Phase I, 2011
SymBio Pharmaceuticals Limited - Pipeline By Therapeutic Class, 2011
SymBio Pharmaceuticals Limited - Pipeline By Target, 2011
SymBio Pharmaceuticals Limited – Pipeline By Route of Administration, 2011
SymBio Pharmaceuticals Limited – Pipeline By Molecule Type, 2011
SymBio Pharmaceuticals Limited – Recent Pipeline Updates, 2011
SymBio Pharmaceuticals Limited, Deals Summary, 2004 to YTD 2011
SymBio Pharmaceuticals Limited, Deals Summary by Region, 2004 to YTD 2011
SymBio Pharmaceuticals Limited, Deals Summary, 2004 to YTD 2011

List of Figures
SymBio Pharmaceuticals Limited – Pipeline by Therapy Area and Indication, 2011
SymBio Pharmaceuticals Limited – Pipeline by Stage of Development, 2011
SymBio Pharmaceuticals Limited – Monotherapy Products in Pipeline, 2011
SymBio Pharmaceuticals Limited – Combination Treatment Modalities in Pipeline, 2011
SymBio Pharmaceuticals Limited – Pipeline By Therapeutic Class, 2011
SymBio Pharmaceuticals Limited - Pipeline By Target, 2011
SymBio Pharmaceuticals Limited – Pipeline By Route of Administration, 2011
SymBio Pharmaceuticals Limited – Pipeline By Molecule Type, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Idenix Pharmaceuticals, Inc.
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Oki Electric Industry Company, Limited
• SunGard - Profile - US
• Abbott Laboratories - IT Sales Opportunities - 2009
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model